2024
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Anderson S, Cavaletti G, Hood L, Polydefkis M, Herrmann D, Rance G, King B, McMichael A, Senna M, Kim B, Napatalung L, Wolk R, Zwillich S, Schaefer G, Gong Y, Sisson M, Posner H. A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata. Pharmacology Research & Perspectives 2024, 12: e1204. PMID: 38969959, PMCID: PMC11226387, DOI: 10.1002/prp2.1204.Peer-Reviewed Original ResearchConceptsIntraepidermal nerve fibersWave V amplitudeInterwave latenciesI-V interwave latencyV amplitudeMonth 9Placebo-controlled phasePhase 2a studyAxonal swellingsIENF densityPlacebo groupBAEP changesLoading doseAdverse eventsRitlecitinibAlopecia areataKinase inhibitorsPrimary outcomeHuman doseToxicity findingsBAEPClinical relevanceNerve fibersPhase 2aStimulus intensityLong‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu W, Yu G, Chiasserini C, Somani N, Holzwarth K, King B. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 583-593. PMID: 38391212, DOI: 10.1111/jdv.19665.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlopeciaAlopecia AreataAzetidinesHumansJanus Kinase InhibitorsPurinesPyrazolesSulfonamidesConceptsSafety of baricitinibSALT scoreSevere alopecia areataPhase 3 trialAlopecia areataSevere AATract infectionsFrequent treatment-emergent adverse eventsMixed respondersWeeks of continuous therapyTreatment-emergent adverse eventsCreatine phosphokinase increaseUpper respiratory tract infectionUrinary tract infectionMaintenance of efficacyProportion of patientsRespiratory tract infectionsTreated with 2 mgLong-term efficacyLong-term treatmentJanus kinase inhibitorsJanus kinaseEyelash regrowthWeek-52Treatment discontinuationIntegrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska N, Paul C, Gong Y, Anway S, Tran H, Wolk R, Zwillich S, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal Of Clinical Dermatology 2024, 25: 299-314. PMID: 38263353, PMCID: PMC10867086, DOI: 10.1007/s40257-024-00846-3.Peer-Reviewed Original ResearchConceptsAdverse eventsAlopecia areataIncidence rateKinase inhibitorsTreatment of alopecia areataPlacebo-controlled cohortAdverse cardiovascular eventsClinical trial programIntegrated safety analysisOpportunistic infectionsPlacebo groupPlacebo-controlledLaboratory abnormalitiesHerpes zosterSafety profileSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Cardiovascular eventsRespiratory syndrome coronavirus 2RitlecitinibObjectiveThe objectivePhase 2aTrial programPatientsMethodsTwo cohorts
2023
Inhibition of T-cell activity in alopecia areata: recent developments and new directions
Passeron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, Tobin D, Randhawa S, Winkler A, Telliez J, Martin D, Lejeune A. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Frontiers In Immunology 2023, 14: 1243556. PMID: 38022501, PMCID: PMC10657858, DOI: 10.3389/fimmu.2023.1243556.Peer-Reviewed Original ResearchMeSH KeywordsAlopecia AreataAutoantigensAutoimmune DiseasesCD8-Positive T-LymphocytesHumansJanus Kinase InhibitorsConceptsT cell-signaling pathwaysAlopecia areataT cellsEtiopathogenesis of AAPathogenesis of AATreatment of AAImmune privilege collapseOnly US FoodHair folliclesSevere alopecia areataT cell activityT cell receptor recognitionLoss of scalpSystemic medicationsAA therapyCytotoxic CD8Inflammatory pathogenesisAutoimmune diseasesTreatment optionsHair lossLimited efficacyTherapeutic pathwaysClinical developmentJAK inhibitionUS FoodEfficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
King B, Zhang X, Harcha W, Szepietowski J, Shapiro J, Lynde C, Mesinkovska N, Zwillich S, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. The Lancet 2023, 401: 1518-1529. PMID: 37062298, DOI: 10.1016/s0140-6736(23)00222-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlopecia AreataCOVID-19Double-Blind MethodFemaleHumansMaleProtein Kinase InhibitorsTreatment OutcomeConceptsAlopecia areataPrimary endpointWeek 24Loading doseExtension periodBaseline disease severitySuitable treatment optionScalp hair lossPatients placeboPlacebo groupWeek 48Systemic therapyAlopecia ToolTreatment optionsPlaceboHair lossPatientsAreataResponse rateDisease severityKinase inhibitorsBody hairMulticentreAfrican AmericansTreatmentEfficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Kwon O, Senna M, Sinclair R, Ito T, Dutronc Y, Lin C, Yu G, Chiasserini C, McCollam J, Wu W, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). American Journal Of Clinical Dermatology 2023, 24: 443-451. PMID: 36855020, PMCID: PMC9974384, DOI: 10.1007/s40257-023-00764-w.Peer-Reviewed Original ResearchConceptsSevere alopecia areataSafety of baricitinibPhase III trialsLong-term treatmentAlopecia areataWeek 52III trialsTract infectionsContinuous therapyFrequent treatment-emergent adverse eventsJanus kinase inhibitor baricitinibTreatment-emergent adverse eventsUpper respiratory tract infectionAlopecia Tool (SALT) scoreWeek 52 resultsCreatine phosphokinase elevationNew safety signalsProportion of patientsRespiratory tract infectionsPermanent treatment discontinuationUrinary tract infectionCoronavirus disease 2019 (COVID-19) pandemicMaximum clinical benefitScalp hair lossCOVID-19 infection
2022
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi G, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang F, Stanley S, Wu W, Sinclair R. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal Of Dermatology 2022, 188: 218-227. PMID: 36763878, DOI: 10.1093/bjd/ljac059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlopecia AreataDouble-Blind MethodHumansJanus Kinase InhibitorsRandomized Controlled Trials as TopicTreatment OutcomeConceptsTreatment-emergent adverse eventsSevere alopecia areataPlacebo-controlled periodAlopecia areataIncidence rateIntegrated safety analysisCreatine phosphokinaseBaricitinib 2Adverse eventsIII trialsClinical trialsSafety dataPhase II/III trialsMajor adverse cardiovascular eventsUpper respiratory tract infectionLong-term extension periodAbnormal laboratory changesDose of baricitinibElevated creatine phosphokinaseAdverse cardiovascular eventsPhase III trialsProportion of patientsRespiratory tract infectionsBlood creatine phosphokinaseOverall safety profile
2021
It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis
Peterson D, Craiglow BG, Mesinkovska NA, Ko J, Senna MM, King B. It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis. Journal Of The American Academy Of Dermatology 2021, 87: e149-e151. PMID: 34678234, DOI: 10.1016/j.jaad.2021.09.056.Peer-Reviewed Original Research
2020
Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. American Journal Of Clinical Dermatology 2020, 21: 725-732. PMID: 32803546, PMCID: PMC7473969, DOI: 10.1007/s40257-020-00545-9.Peer-Reviewed Original ResearchConceptsSigns/symptomsAlopecia areataPRO measuresNail appearanceEyelash lossOutcome measuresHair lossEye irritationPatient-reported outcome measuresClinician-reported outcomesNorth American patientsDevelopment of cliniciansNail assessmentEyebrow lossNail involvementAmerican patientsClinical trialsPatientsNail damageSymptomsAreataObjectivesOur objectiveOutcomesEyelashesDermatologistsDevelopment of the Scalp Hair Assessment PRO™ measure for alopecia areata
Wyrwich K, Kitchen H, Knight S, Aldhouse N, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King B. Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. British Journal Of Dermatology 2020, 183: 1065-1072. PMID: 32163589, PMCID: PMC7754291, DOI: 10.1111/bjd.19024.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlopeciaAlopecia AreataHairHumansNorth AmericaPatient Reported Outcome MeasuresScalpConceptsScalp hair lossHair lossPRO measuresValid patient-reported outcome measurePatient-reported outcome measuresAlopecia areata treatmentInvestigator's Global AssessmentHair regrowthAlopecia areataTreatment successOutcome measuresQualitative semistructured interviewsPatientsGlobal assessmentAA treatmentClinical expertsScalp hairSemistructured interviewsTreatmentAreataResponse scaleSymptomsBaselineAAMeasuresThe Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
Wyrwich K, Kitchen H, Knight S, Aldhouse N, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King B. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. British Journal Of Dermatology 2020, 183: 702-709. PMID: 31970750, PMCID: PMC7586961, DOI: 10.1111/bjd.18883.Peer-Reviewed Original ResearchConceptsInvestigator's Global AssessmentScalp hair lossAlopecia areataTreatment successGlobal assessmentAlopecia ToolClinical trialsClinician's perspectiveScalp hairTreatment studiesInvestigator's Global Assessment (IGA) scaleSigns/symptomsScalp hair growthGlobal Assessment ScaleMost patientsAdolescent patientsHair regrowthClinical evaluationExpert dermatologistsSuccessful treatmentClinical consensusTreatment outcomesPatient insightTreatment responseAdditional cliniciansThe Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata
Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, Bergfeld WF, Betz RC, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Donovan J, Eisman S, Farrant P, Green J, Grimalt R, Harries M, Hordinsky M, Irvine AD, Itami S, Jolliffe V, King B, Lee WS, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Piraccini BM, Rakowska A, Reygagne P, Roberts JL, Rudnicka L, Shapiro J, Sharma P, Tosti A, Vogt A, Wade M, Yip L, Zlotogorski A, Sinclair R. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. Journal Of The American Academy Of Dermatology 2020, 83: 123-130. PMID: 32165196, DOI: 10.1016/j.jaad.2020.03.004.Peer-Reviewed Original ResearchConceptsAlopecia areataSystemic therapyTreatment-specific questionsInternational consensus statementInternational patient registriesInternational expert opinionNonprescription therapiesSystemic treatmentIntralesional treatmentPatient RegistryTopical treatmentConsensus statementExpert consensusSystematic reviewTherapyDelphi processLeast consensusTreatmentAreataHair expertsExpert opinionRobust evidenceFurther researchFirst roundConsensus
2019
Combination tofacitinib and oral minoxidil treatment for severe alopecia areata
Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. Journal Of The American Academy Of Dermatology 2019, 85: 743-745. PMID: 31499158, DOI: 10.1016/j.jaad.2019.08.080.Peer-Reviewed Original ResearchRule of thumb: A simple tool to estimate 1% scalp surface area
Wambier CG, King BA. Rule of thumb: A simple tool to estimate 1% scalp surface area. Journal Of The American Academy Of Dermatology 2019, 81: 630-631. PMID: 30682394, DOI: 10.1016/j.jaad.2019.01.022.Peer-Reviewed Original Research
2018
Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata
Liu LY, King BA. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: 1778-1779. PMID: 30502414, DOI: 10.1016/j.jaad.2018.11.037.Peer-Reviewed Original ResearchRethinking the classification of alopecia areata
Wambier C, King B. Rethinking the classification of alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: e45. PMID: 30244065, DOI: 10.1016/j.jaad.2018.08.059.Peer-Reviewed Original ResearchRuxolitinib for the treatment of severe alopecia areata
Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: 566-568. PMID: 30195572, DOI: 10.1016/j.jaad.2018.08.040.Peer-Reviewed Original ResearchTofacitinib for the treatment of alopecia areata in preadolescent children
Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. Journal Of The American Academy Of Dermatology 2018, 80: 568-570. PMID: 30195571, DOI: 10.1016/j.jaad.2018.08.041.Peer-Reviewed Original ResearchAlopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families
Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. Journal Of The American Academy Of Dermatology 2018, 79: 556-558.e1. PMID: 29425723, DOI: 10.1016/j.jaad.2018.01.048.Peer-Reviewed Original Research
2017
Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life
Liu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. Journal Of The American Academy Of Dermatology 2017, 78: 597-599.e2. PMID: 29128459, DOI: 10.1016/j.jaad.2017.10.046.Peer-Reviewed Original Research